Skip to main content
Premium Trial:

Request an Annual Quote

Reel Two Acquires Gene-Searching Software from New Zealand Biotech

NEW YORK, April 11 (GenomeWeb News) - Biomedical text-mining firm Reel Two has acquired the rights to high-throughput gene searching technology that it developed for Genesis Research and Development, a therapeutic-development company based in New Zealand.


The software, called Cartesian, was written for in-house use at Genesis. The firms recently reached an agreement under which Reel Two owns the patents and gains the right to commercialize the software, while Genesis will be entitled to a share of the revenues.


"Reel Two has worked closely with Genesis to develop the Cartesian software and is the ideal party to take the product to market," said Stephen Hall, CEO of Genesis, in a statement.


According to Genesis, the Cartesian software has been designed to perform "very fast searching of genetic sequences." The company said that in internal use, the software "reduced analysis and computation time by many orders of magnitude, reducing tasks that had previously taken many months on a large computer cluster down to hours on a single machine."


Further financial terms of the agreement were not disclosed.


This article originally appeared in BioInform, a GenomeWeb News publication.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.